Inhibiting "anchor" molecule in stem cells may improve marrow transplant process

The safety and efficiency of bone marrow transplants may improve due to the discovery of a rare molecule that establishes blood stem cells in their niche within the bone marrow.

The molecule—Robo4—is found only in the hematopoietic stem cells and in the endothelial cells of blood vessels. According to the new study findings, published in Cell Stem Cell (2011;8:72-83), hematopoietic stem cells—the key components in bone marrow transplants—use Robo4 to anchor themselves in the bone marrow where they reside.

In an increasingly common alternative to traditional bone marrow transplants, repeated drug injections are administered to usher stem cells away from bone marrow and into the bloodstream, from which they can be harvested and eventually groomed into different types of cells. The Robo4 discovery, however, creates an opportunity to find agents that can block the molecule in a safer and more effective fashion.

“If we can get specific and efficient inhibition of Robo4, we might be able to mobilize the hematopoietic stem cells to the blood more efficiently,” explained E. Camilla Forsberg, an assistant professor of biomolecular engineering at University of California–Santa Cruz, in a statement describing her team's work.

 

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Drug combination shrinks tumors in patients with advanced melanoma

Combining ipilimumab and the investigational antibody nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma.

Bevacizumab added to initial glioblastoma treatment does not extend lives

Adding bevacizumab to initial treatment for glioblastoma did not improve overall patient survival or progression-free survival, according to results of a randomized phase III trial.

Digital chest tomography may be first stop in lung cancer screening

Digital chest tomosynthesis holds promise as a first-line tool for lung cancer screening, according to the baseline results of a single-arm, observational study.